Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24547777 | 0.79 | IDH1 (0.37) | ALDH1A1LMNAKDM4EHTTHSD11B1 | |
| SCHEMBL24547754 | 0.78 | HPGD (0.42) | ALDH1A1LMNAMAPTKDM4EHTT | |
| SCHEMBL27112816 | 0.78 | HPGD (0.36) | ALDH1A1LMNAMAPTKDM4ETSHR | |
| SCHEMBL24547744 | 0.75 | KDM4E (0.45) | SMN1; SMN2ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL24547758 | 0.75 | ELANE (0.46) | CNR2ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL24547757 | 0.74 | ELANE (0.45) | CNR2ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL24547660 | 0.74 | ELANE (0.45) | CNR2ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL24547762 | 0.73 | HSD17B10 (0.41) | CNR2ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL24547742 | 0.73 | P2RX4 (0.56) | SMN1; SMN2ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL29875900 | 0.73 | CNR2 (0.46) | SMN1; SMN2CNR2ALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067654-A1 | OXYTOCIN RECEPTOR MODULATORS | Kinoxis Therapeutics Pty Ltd (AU) | 2024-02-29 | — | — | US | disclosed |
| US-20240067654-A1 | OXYTOCIN RECEPTOR MODULATORS | Kinoxis Therapeutics Pty Ltd (AU) | 2024-02-29 | — | — | US | disclosed |
| WO-2022126179-A1 | OXYTOCIN RECEPTOR MODULATORS | THE UNIVERSITY OF SYDNEY (AU) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067654-A1 | OXYTOCIN RECEPTOR MODULATORS | OXTR, AVPR1B, AVPR1A | SMN1; SMN2 3798/4885CNR2 234/4885ALDH1A1 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.